Luye Pharma Group (STU:LUP) 3-Year Revenue Growth Rate : -4.30% (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Luye Pharma Group 3-Year Revenue Growth Rate?

Luye Pharma Group's Revenue per Share for the six months ended in Dec. 2023 was €0.11.

During the past 12 months, Luye Pharma Group's average Revenue per Share Growth Rate was -6.10% per year. During the past 3 years, the average Revenue per Share Growth Rate was -4.30% per year. During the past 5 years, the average Revenue per Share Growth Rate was -1.60% per year. During the past 10 years, the average Revenue per Share Growth Rate was -0.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Luye Pharma Group was 48.90% per year. The lowest was -46.70% per year. And the median was 9.20% per year.

Competitive Comparison of Luye Pharma Group's 3-Year Revenue Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Luye Pharma Group's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Luye Pharma Group's 3-Year Revenue Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Luye Pharma Group's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Luye Pharma Group's 3-Year Revenue Growth Rate falls into.

Luye Pharma Group 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Luye Pharma Group (STU:LUP) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Luye Pharma Group 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Luye Pharma Group's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Luye Pharma Group (STU:LUP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Luye Pharma Group Ltd (STU:LUP) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

LYPHF:USA 02186:Hong Kong

Address

No. 15 Chuang Ye Road, High-tech Industrial Development Zone, Shandong, Yantai, CHN, 264003

Website

https://www.luye.cn

Luye Pharma Group Ltd is a China-based drug manufacturer that focuses on developing, producing, and selling pharmaceutical products. The company develops drugs related to diagnosing and treating cancer, the cardiovascular system, the alimentary tract, and the central nervous system. The company's highest revenue share comes from oncology drugs, followed by central nervous system drugs. The company develops drugs for global use in Asia, Europe, and the United States.

Luye Pharma Group (STU:LUP) Headlines

No Headlines